How to add peptide therapy to your practice

To add peptide therapy to your practice, evaluate the specific drug, intended use, human evidence, safety, and lawful supply pathway before advertising a service. Peptide therapy is not one treatment with one evidence base. Confirm your scope and coverage, check the exact product’s regulatory status, and create a documented review, consent, monitoring, and follow-up process for any service you decide to offer.

What should you review before adding peptide therapy?

Start with a clinical question, not a broad service label. Identify the condition, the outcome you hope to address, and the exact product and route under consideration. Then compare human evidence, known risks, and better-established alternatives. A plausible mechanism, animal study, or pharmacy's willingness to supply a product does not establish a benefit for patients.

Use this review worksheet for each proposed therapy:

Review question	Evidence or document to collect
What is the clinical purpose?	Defined patient population, indication, and meaningful outcome
What human evidence exists?	Guidelines and human studies relevant to that population and route
What is known about risk?	Label warnings where applicable, human safety data, and FDA alerts
Is there an alternative?	Evidence for available options addressing the same goal
What is the regulatory status?	Product approval status and the applicable compounding pathway, if relevant
Can the practice deliver it responsibly?	Scope, coverage, consent, documentation, monitoring, and escalation plan

This is a process for evaluating a proposed service, not a recommendation for a peptide or dosing protocol.

How do approved and compounded products differ?

FDA approval applies to a specific drug product, not to the word peptide or every preparation containing a related substance. Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before marketing. Compounding can address a medical need, but poor-quality or contaminated preparations can cause serious harm. FDA explanation of compounded-drug risks

Keep those distinctions visible in patient information. Do not describe a compounded preparation as approved because another product has an approval, or treat registration of a facility as approval of its products. Review the exact formulation, route, indication, and regulatory pathway. FDA compounding questions and answers

What do sections 503A and 503B mean for a practice?

Sections 503A and 503B describe different federal compounding pathways and conditions. Section 503A is generally based on a prescription for an identified individual patient, with limited anticipatory compounding provisions. Section 503B covers qualifying registered outsourcing facilities and does not require every compounded drug to be tied to an individual prescription. Compounded drugs are not FDA-approved under either pathway.

Pathway	Main distinction	What still needs review
Section 503A	Compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, under the section's patient-specific conditions	Prescription, ingredients, copy restrictions, state requirements, and the other statutory conditions
Section 503B	Compounding by or under a licensed pharmacist at a qualifying registered outsourcing facility	Registration, manufacturing and reporting duties, permitted ingredients, and the other statutory conditions

Sources: 21 U.S.C. 353a, 21 U.S.C. 353b, and FDA's compounding overview, checked October 12, 2026. The linked U.S. Code pages are the 2023 edition; use FDA's current guidance and legal review for a proposed product.

Bulk ingredients have additional restrictions. FDA explains the 503A routes through applicable pharmacopeial standards, approved-drug components where appropriate, or the regulatory bulks list, and describes its interim enforcement policy. A nomination or category listing is not drug approval or evidence of clinical benefit. FDA bulk-substance guidance

Which safety questions deserve attention before launch?

Review FDA safety information for the exact substance and route, alongside the human evidence. As of October 12, 2026, FDA's compounding safety page identifies several substances with limited safety information, peptide-impurity concerns, or potential immune reactions. Limited evidence is a reason to document uncertainty; it is not evidence that a treatment is safe.

For example, FDA identifies limited safety information and potential immunogenicity and impurity concerns for BPC-157. It identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, while noting limited clinical data. These examples illustrate the need for product-specific review, not a menu of services to offer. FDA safety-risk page

If you cannot establish an acceptable evidence, safety, and legal basis for the proposed service, do not add it on the strength of patient demand or vendor claims.

What should the clinical workflow document?

Document why the proposed treatment fits the patient, what evidence and uncertainty were discussed, what alternatives were considered, and how follow-up will work. Identify who receives results and adverse-event reports and who covers the service when the treating clinician is away. Tailor the workflow to the specific therapy rather than reusing a generic peptide consent.

For a compounded drug, include its identity and the patient-specific reason for compounding. If relying on a significant difference from a comparable commercial product under section 503A, the statute places that determination with the prescriber for the identified patient. 21 U.S.C. 353a

Ask the insurer to confirm the proposed services in writing. Check state scope and any required physician agreement separately; a course completion certificate does not establish that the service is within your licensed practice.

How should you prepare the business side?

Once the clinical and legal review supports a service, define the visit, follow-up, costs, and administrative responsibilities. Explain which fees belong to the practice and which are billed by other parties. Avoid promises of clinical results or insurance reimbursement. Use the cash-pay guide for estimates and payment rules.

If the service is part of a new practice, the private practice guide covers setup, and the longevity clinic guide covers broader service planning. Review any employment restrictions before starting outside work.

This guide is for licensed clinicians planning a service. It is not a treatment protocol or legal advice. Care decisions remain with independent licensed clinicians.

Vye Health helps providers launch, run, and grow private practices.

Apply to Vye Health.